Phase 2
N=126
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Motion Sickness
Bottom Line
View on ClinicalTrials.gov: NCT03772340 ↗Enrolled (actual)
126
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: The Most Severe Motion Sickness Severity During Vehicle Travel — 3.4; 3.75 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Tradipitant (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Vanda Pharmaceuticals
- Primary completion
- Jun 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Most Severe Motion Sickness Severity During Vehicle Travel |
3.4; 3.75 | — |
| PRIMARY Percentage of Vomiting |
52; 38; 11; 25 | — |
Summary
Randomized, double-blind, placebo-controlled investigating the efficacy of tradipitant in the treatment of motion sickness.
Eligibility Criteria
Inclusion Criteria
- Male or non-pregnant, non-lactating female patients aged 18 - 75 years (inclusive);
- Body Mass Index (BMI) of ≥18 and <40 kg/m2;
- History or symptoms consistent with motion sickness
Exclusion Criteria
- Chronic nausea due to condition other than motion sickness;
- A positive test for drugs of abuse at the screening or evaluation visits;
- Clinically significant deviation from normal clinical laboratory results
Data sourced from ClinicalTrials.gov (NCT03772340). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.